{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:45:03Z","timestamp":1784555103940,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jinf.2023.06.022","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T17:45:29Z","timestamp":1688406329000},"page":"242-254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial"],"prefix":"10.1016","volume":"87","author":[{"given":"Christian","family":"Taucher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeka","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Dellago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petronela","family":"Weisova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1127-7123","authenticated-orcid":false,"given":"Irena","family":"Corbic-Ramljak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Dubischar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Lilja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Eder-Lingelbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romana","family":"Hochreiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Jaramillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helga","family":"Junker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Pusic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9846-8626","authenticated-orcid":false,"given":"Benedicte","family":"Querton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3169-1900","authenticated-orcid":false,"given":"Julian","family":"Larcher-Senn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4603-7696","authenticated-orcid":false,"given":"Markus","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6086-9136","authenticated-orcid":false,"given":"Stefan","family":"P\u00f6hlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jinf.2023.06.022_bib1","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41562-021-01122-8","article-title":"A global database of COVID-19 vaccinations","volume":"5","author":"Mathieu","year":"2021","journal-title":"Nat Hum Behav"},{"issue":"10269","key":"10.1016\/j.jinf.2023.06.022_bib2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"issue":"27","key":"10.1016\/j.jinf.2023.06.022_bib3","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med [Internet]"},{"issue":"1","key":"10.1016\/j.jinf.2023.06.022_bib4","first-page":"1","article-title":"Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil","volume":"13","author":"Ranzani","year":"2022","journal-title":"Nat Commun 2022 131 [Internet]"},{"issue":"9","key":"10.1016\/j.jinf.2023.06.022_bib5","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","article-title":"Global impact of the first year of COVID-19 vaccination: a mathematical modelling study","volume":"22","author":"Watson","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"10328","key":"10.1016\/j.jinf.2023.06.022_bib6","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression","volume":"399","author":"Feikin","year":"2022","journal-title":"Lancet [Internet]"},{"issue":"7","key":"10.1016\/j.jinf.2023.06.022_bib7","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1001\/jama.2022.0470","article-title":"Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants","volume":"327","author":"Accorsi","year":"2022","journal-title":"JAMA [Internet]"},{"issue":"4","key":"10.1016\/j.jinf.2023.06.022_bib8","first-page":"838","article-title":"Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil","volume":"28","author":"Cerqueira-Silva","year":"2022","journal-title":"Nat Med 2022 284 [Internet]"},{"issue":"24","key":"10.1016\/j.jinf.2023.06.022_bib9","article-title":"Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar","volume":"385","author":"Chemaitelly","year":"2021","journal-title":"N Engl J Med [Internet]"},{"key":"10.1016\/j.jinf.2023.06.022_bib10","article-title":"Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study","volume":"10","author":"Naaber","year":"2021","journal-title":"Lancet Reg Heal - Eur"},{"issue":"8","key":"10.1016\/j.jinf.2023.06.022_bib11","article-title":"Protective antibodies and T cell responses to Omicron variant after the booster dose of BNT162b2 vaccine","volume":"3","author":"Naaber","year":"2022","journal-title":"Cell Rep Med"},{"issue":"16","key":"10.1016\/j.jinf.2023.06.022_bib12","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N Engl J Med [Internet]"},{"issue":"1","key":"10.1016\/j.jinf.2023.06.022_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-022-32312-1","article-title":"Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose","volume":"13","author":"Renia","year":"2022","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.jinf.2023.06.022_bib14","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41591-022-01704-7","article-title":"Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination","volume":"28","author":"Cheng","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jinf.2023.06.022_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-022-30864-w","article-title":"Six-month follow-up of a booster dose of CoronaVac in two single-centre phase 2 clinical trials","volume":"13","author":"Xin","year":"2022","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.jinf.2023.06.022_bib16","first-page":"831","article-title":"Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England","volume":"28","author":"Andrews","year":"2022","journal-title":"Nat Med 2022 284 [Internet]"},{"issue":"7","key":"10.1016\/j.jinf.2023.06.022_bib17","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S1473-3099(22)00146-3","article-title":"COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID study","volume":"22","author":"Menni","year":"2022","journal-title":"Lancet Infect Dis [Internet]"},{"issue":"6","key":"10.1016\/j.jinf.2023.06.022_bib18","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41577-021-00550-x","article-title":"Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection","volume":"21","author":"Cromer","year":"2021","journal-title":"Nat Rev Immunol [Internet]"},{"key":"10.1016\/j.jinf.2023.06.022_bib19","unstructured":"Mathieu E, Ritchie H, Rod\u00e9s-Guirao L, Appel C, Giattino C, Hasell J, et al. Coronavirus pandemic (COVID-19) [Internet]; 2020 [cited 2023 May 4]. Available from: \u3008https:\/\/ourworldindata.org\/coronavirus\u3009."},{"issue":"13","key":"10.1016\/j.jinf.2023.06.022_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2807\/1560-7917.ES.2020.25.13.2000305","article-title":"Whole genome and phylogenetic analysis of two SARSCoV-2 strains isolated in Italy in January and February 2020: additional clues on multiple introductions and further circulation in Europe","volume":"25","author":"Stefanelli","year":"2020","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.jinf.2023.06.022_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(22)00502-3","article-title":"Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial","author":"Lazarus","year":"2022","journal-title":"Lancet Infect Dis [Internet]"},{"key":"10.1016\/j.jinf.2023.06.022_bib22","first-page":"1","article-title":"COVID-19 vaccine (inactivated, adjuvanted) Valneva assessment report [Internet]","author":"European Medicines Agency","year":"2022","journal-title":"Eur Med Agency"},{"issue":"10","key":"10.1016\/j.jinf.2023.06.022_bib23","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1002\/jmv.25986","article-title":"Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples","volume":"92","author":"Manenti","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.jinf.2023.06.022_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cell.2021.03.036","article-title":"Article SARS-CoV-2 variants B. 1. 351 and P. 1 escape from neutralizing antibodies Article escape from neutralizing antibodies","volume":"184","author":"Hoffmann","year":"2021","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.jinf.2023.06.022_bib25","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1038\/s41423-021-00772-y","article-title":"Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance","volume":"18","author":"Arora","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jinf.2023.06.022_bib26","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S1473-3099(22)00422-4","article-title":"Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5. Vol. 22","author":"Arora","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jinf.2023.06.022_bib27","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials [Internet]. Vol. September; 2007 [cited 2022 Oct 19]. p. 1\u201310. Available from: \u3008http:\/\/www.fda.gov\/cber\/guidelines.htm\u3009."},{"key":"10.1016\/j.jinf.2023.06.022_bib28","unstructured":"Department of Health & Social Care. JCVI statement on use of the AstraZeneca COVID-19 vaccine: 7 April 2021 [Internet]. Independent Report; 2021 [cited 2023 Jun 14]. Available from: \u3008https:\/\/www.gov.uk\/government\/publications\/use-of-the-astrazeneca-covid-19-vaccine-jcvi-statement\/jcvi-statement-on-use-of-the-astrazeneca-covid-19-vaccine-7-april-2021\u3009."},{"issue":"4","key":"10.1016\/j.jinf.2023.06.022_bib29","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1473-3099(21)00681-2","article-title":"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials","volume":"22","author":"Zeng","year":"2022","journal-title":"Lancet Infect Dis [Internet]"},{"issue":"5","key":"10.1016\/j.jinf.2023.06.022_bib30","first-page":"1042","article-title":"Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial","volume":"28","author":"Chu","year":"2022","journal-title":"Nat Med 2022 285 [Internet]"},{"issue":"1","key":"10.1016\/j.jinf.2023.06.022_bib31","first-page":"1","article-title":"BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19\/BNT162b2 vaccination against COVID-19","volume":"13","author":"Behrens","year":"2022","journal-title":"Nat Commun 2022 131 [Internet]"},{"issue":"10318","key":"10.1016\/j.jinf.2023.06.022_bib32","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"issue":"6576","key":"10.1016\/j.jinf.2023.06.022_bib33","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science (80-) [Internet]"},{"issue":"11","key":"10.1016\/j.jinf.2023.06.022_bib34","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1056\/NEJMc2119912","article-title":"SARS-CoV-2 Omicron variant neutralization after mRNA-1273 booster vaccination","volume":"386","author":"Pajon","year":"2022","journal-title":"N Engl J Med"},{"issue":"7898","key":"10.1016\/j.jinf.2023.06.022_bib35","first-page":"671","article-title":"Considerable escape of SARS-CoV-2 Omicron to antibody neutralization","volume":"602","author":"Planas","year":"2021","journal-title":"Nature 2021 6027898 [Internet]"},{"issue":"6600","key":"10.1016\/j.jinf.2023.06.022_bib36","doi-asserted-by":"crossref","DOI":"10.1126\/science.abq4411","article-title":"Twin peaks: the Omicron SARS-CoV-2 BA.1 and BA.2 epidemics in England","volume":"376","author":"Elliott","year":"2022","journal-title":"Science (80-)"},{"issue":"7","key":"10.1016\/j.jinf.2023.06.022_bib37","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1473-3099(22)00309-7","article-title":"COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England","volume":"22","author":"Kirsebom","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"6529","key":"10.1016\/j.jinf.2023.06.022_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science (80-)"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445323003675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445323003675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:37:31Z","timestamp":1759009051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445323003675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0163445323003675"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2023.06.022","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2023.06.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd on behalf of The British Infection Association.","name":"copyright","label":"Copyright"}]}}